EPH135 Impact of Resmetirom on Liver Transplant Demand and Outcomes in US Patients With MASH

Journal article

Peer reviewed

EPH135 Impact of Resmetirom on Liver Transplant Demand and Outcomes in US Patients With MASH

Daniel Kim, Yestle Kim, Michael Charlton, John O'Donnell, Nipun Atreja, Mert Sahinkoc, Gizem Sultan Nemutlu and Jag Chhatwal

Value in health, Vol.28(12), pp.S290-S290

12/2025

DOI: https://doi.org/10.1016/j.jval.2025.09.1264

Metrics

1 Record Views

Details

Title: EPH135 Impact of Resmetirom on Liver Transplant Demand and Outcomes in US Patients With MASH
Creators: Daniel Kim - Harvard Medical School
Yestle Kim - Madrigal Pharmaceuticals (United States)
Michael Charlton - Madrigal Pharmaceuticals (United States)
John O'Donnell - Madrigal Pharmaceuticals (United States)
Nipun Atreja - Madrigal Pharmaceuticals (United States)
Mert Sahinkoc - Harvard Medical School
Gizem Sultan Nemutlu - Brandeis University
Jag Chhatwal - Harvard Medical School
Publication Details: Value in health, Vol.28(12), pp.S290-S290
Publisher: Elsevier Inc
Identifiers: 9924560390901921
Academic Unit: Brandeis International Business School
Language: English
Resource Type: Journal article